Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1046 monotherapy and GEN1046 plus pembrolizumab in relapsed/refractory metastatic non-small cell lung cancer after prior checkpoint inhibitor therapy
NL-OMON54259Phase 2Recruiting
- Sponsor
- Genmab
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acasunlimab and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Genmab. Primary endpoint: Objective response rate. Started Feb 2023; status: recruiting.
02
Drugs
acasunlimabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54259.